# Tolerability and Safety of Nano-Tocotrienols

Study · id `cardio:ct-nct07888426` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07888426](<https://clinicaltrials.gov/study/NCT07888426>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07888426

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 360 participants.

## Technical summary

Registry record NCT07888426. Randomized; double masking; primary purpose other. Start 2026-10 (anticipated); primary completion 2029-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose other
- Phase: Phase 2
- Enrolled: 360 participants (planned count; ClinicalTrials.gov record NCT07888426, source copy `cardio:ctgov-nct07888426-2026-10-22`, retrieved 2026-10-26)
- Planned start: 2026-10 (anticipated) (ClinicalTrials.gov record NCT07888426, source copy `cardio:ctgov-nct07888426-2026-10-22`, retrieved 2026-10-26)
- Primary completion: 2029-10 (anticipated) (ClinicalTrials.gov record NCT07888426, source copy `cardio:ctgov-nct07888426-2026-10-22`, retrieved 2026-10-26)
- Completion: 2029-10 (anticipated) (ClinicalTrials.gov record NCT07888426, source copy `cardio:ctgov-nct07888426-2026-10-22`, retrieved 2026-10-26)
- Countries: Malaysia (ClinicalTrials.gov record NCT07888426, source copy `cardio:ctgov-nct07888426-2026-10-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07888426-2026-10-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Tolerability and Safety of Nano-Tocotrienols
- Condition: Type 2 Diabetes Mellitus (DM)
- Intervention (Drug): Nano-tocotrienols
- Intervention (Drug): Placebo
- Lead sponsor: University of Malaya
- Lead sponsor class: OTHER
- Collaborator: Malaysia Palm Oil Board
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: bc099b5ebea92e4f48e4ebc955ffecd6a41584c751d89ed80388f0f9067b794e
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
